Search

313 Result(s)
Sort by

Living With Cancer

Living With Cancer

Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
“My ultimate goal is to cure cancer”

“My ultimate goal is to cure cancer”

Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Our goal of transforming the treatment of neuroendocrine carcinomas

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Taking Cancer on at Diagnosis

Taking Cancer on at Diagnosis

We spoke to Markus, Brigitte and Dr Hochmair who shared their advice for people starting their own cancer journeys.
GioTag Final Data

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Four Pillars Cancer Immunology

Four Pillars Cancer Immunology

Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Cancer's Big 4

Cancer's Big 4

We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease